Altamira Therapeutics Ltd. Basic Earnings Loss Per Instrument From Continuing Operations Participating Equity Instruments Other Than Ordinary Shares
Altamira Therapeutics Ltd. (CYTOF) reported Basic Earnings Loss Per Instrument From Continuing Operations Participating Equity Instruments Other Than Ordinary Shares of -$2.99 per share for the 12-month period ending 2024-12-31, per its 20-F filed 2025-04-30.
Financial Statements › Notes › Per Share
ifrs-full:BasicEarningsLossPerInstrumentFromContinuingOperationsParticipatingEquityInstrumentsOtherThanOrdinaryShares · last filed 2025-04-30
CHF/shares
| Period end | Basic Earnings Loss Per Instrument From Continuing Operations Participating Equity Instruments Other Than Ordinary Shares 12 month |
|---|---|
| 2023-12-31 | -14.80 CHF/shares 20-F/A · filed 2024-04-22 |
| 2022-12-31 | -409.60 CHF/shares 20-F/A · filed 2024-04-22 |
| 2021-12-31 | -201.97 CHF/shares 20-F/A · filed 2024-04-22 |
USD/shares
| Period end | Basic Earnings Loss Per Instrument From Continuing Operations Participating Equity Instruments Other Than Ordinary Shares 12 month |
|---|---|
| 2024-12-31 | -$2.99 20-F · filed 2025-04-30 |
| 2023-12-31 | -$16.47 20-F · filed 2025-04-30 |
| 2022-12-31 | -$428.90 20-F · filed 2025-04-30 |